Impel Pharmaceuticals is the first company to investigate targeting the upper nasal space with optimized therapeutic molecules and formulations for treating CNS diseases.
As a result, Impel Pharmaceuticals’ therapies have the potential to improve the onset of symptomatic relief for a spectrum of neurological conditions. Today, Impel Pharmaceuticals is commercializing and providing treatments that use this gateway to deliver therapies for patients living with CNS diseases with high unmet medical needs.
Impel Pharmaceuticals’ mission is to create and provide transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the CNS. We have pioneered an approach to drug delivery that administers specific formulations of drugs deep into the vascular-rich upper nasal space, a gateway for therapeutic administration of a versatile range of molecules and formulations.
Our Core Values
Innovation is our Passion. We embrace change and encourage opportunities for creative thinking.
People as One. We nurture our people and empower teams to enable the impossible.
Customer Focus. We have unwavering commitment to satisfying the needs of patients and customers.
Executional Excellence. We plan for success and deliver with agility, quality, and excellence.
Integrity and Compliance. We hold ourselves to the highest operational, compliance and ethical standards.
We strive to create life-changing innovative therapies for CNS diseases.
Impel Pharmaceuticals is developing and providing therapies that have the potential to achieve rapid, extensive, and consistent bioavailability of medicine to improve clinical outcomes for patients non-invasively. Trudhesa® (dihydroergotamine mesylate) nasal spray is approved in the U.S. for the acute treatment of migraine with or without aura in adults.
Impel Pharmaceuticals continues to advance late-stage clinical development programs to address patient needs. In addition to Trudhesa, Impel is developing INP105 for the acute treatment of agitation aggression associated with agitation and autism spectrum disorder (ASD), and INP107 for OFF episodes in Parkinson’s disease.
1 Data on File